Compare Ascendis Pharma A/S (ASND) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.51. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| ASND | BIL | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $91.77 |
52-Week Low | $163.32 | $91.27 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) trades at $91.50 with minimal daily movement, reflecting its stable Treasury bill portfolio. The ETF maintains consistent $0.27 quarterly dividends and shows bearish technical signals despite neutral oscillators. Recent market focus compares short-term Treasury ETFs like BIL against money market alternatives as investors seek yield amid Federal Reserve policy uncertainty.
BIL offers low-risk cash parking with Treasury bill exposure, but faces pressure from potential Fed rate hikes that could impact short-term yields. The ETF's stability appeals to risk-averse investors, though higher-yielding alternatives may emerge if rates rise further. Current technical weakness suggests cautious near-term positioning despite fundamental safety.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
